The Python extension now supports multi-project workspaces, where each Python project within a workspace gets its own test tree and Python environment. This document explains how multi-project testing ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. Quest Flow ...

SECAUCUS, N.J. - Quest Diagnostics (NYSE:DGX) introduced a new blood test on Monday that detects measurable residual disease (MRD) in myeloma patients using advanced flow cytometry methods. The ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the Alliance for Clinical Trials in Oncology today announced publication of the ...

Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely ...

"Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients ...

PALO ALTO, Calif. & ROCHESTER, Minn., February 02, 2026--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company and research collaborators at Mayo Clinic and the ...

Assessing adjuvant chemotherapy benefit in younger and older molecular residual disease–positive patients with stage II/III colorectal cancer. This is an ASCO Meeting Abstract from the 2026 ASCO ...

Abstract: This paper presents PyResBugs, a curated dataset of residual bugs, i.e., defects that persist undetected during traditional testing but later surface in production—collected from major ...

Residuals are one of the most essential forms of compensation for DGA members. They ensure that when work continues to generate revenue over time, the people who made it possible share in that ongoing ...